GB Sciences Licenses Patent To Develop New Cannabis-Based Therapies For The Treatment Of Heart Disease

LAS VEGAS, Dec. 13, 2016, GBLX, /PRNewswire/ GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that its wholly-owned subsidiary, Growblox Life Sciences, LLC has licensed intellectual property from Makai Biotechnology, LLC. The patent underlying the license was issued by the USPTO in July of 2015, and claims therapeutic methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1. TRPV1 can be regulated therapeutically by plant-based cannabinoids, which creates a plethora of
http://bit.ly/2gyjIz2